9/28/2020 6:09:40 AM
Aurinia Completes Final Patient Treatment In AUDREY Phase 2/3 Clinical Trial Of Voclosporin Ophthalmic Solution
7/27/2020 10:34:12 AM
Aurinia Closes $200 Mln Public Offering Of Common Shares
7/22/2020 11:11:24 PM
Aurinia Pharma Announces Pricing Of Underwritten Public
offering Of 13.33 Mln Shares At US$15.00/shr
6/22/2020 6:09:21 AM
Aurinia Completes Patient Enrollment Into AUDREY Phase 2/3 Clinical Trial Of Voclosporin Ophthalmic Solution
6/9/2020 6:10:21 AM
Aurinia Pharma Presents Addl AURORA Pivotal Trial Safety Data At ERA-EDTA Virtual Congress 2020
6/5/2020 7:11:24 AM
AbbVie, Harbour BioMed, Utrecht University And Erasmus Medical Center Announcee Collaboation
6/5/2020 7:09:05 AM
Aurinia Presents New Subgroup Analyses From Completed AURORA Pivotal Trial Of Voclosporin
6/3/2020 6:08:48 AM
Aurinia Pharma Says Nine Incumbent Directors Elected At Annual General Meeting
5/26/2020 6:08:41 AM
Aurinia Completes Submission Of NDA To FDA For Voclosporin For Treatment Of Lupus Nephritis
5/14/2020 4:04:02 PM
Aurinia Q1 Loss/share $0.15 Vs. Loss $0.14 Year Ago
4/27/2020 6:08:38 AM
Aurinia Appoints Joe Miller As CFO
4/20/2020 6:11:31 AM
Aurinia Appoints Timothy Walbert To Board
3/18/2020 6:07:08 AM
Aurinia Announces AURORA Phase 3 Clinical Data For Voclosporin To Be Presented At NKF 2020 Spring Clinical Meetings
3/17/2020 6:02:48 AM
Aurinia Pharma Establishes U.S. Commercial Operations Center In Rockville, Maryland
3/16/2020 6:21:11 AM
Aurinia Initiates Rolling Submission Of NDA To FDA For Voclosporin
3/12/2020 7:08:24 AM
Aurinia Pharma Announces New Initiatives To Support Lupus Nephritis Community And Raise Disease Awareness
12/12/2019 9:29:04 AM
Aurinia Closes Public Offering Of 12.78 Mln Common Shares